The United States Supreme Court is currently evaluating the legality of telemedicine-based distribution of mifepristone following a conflicting ruling from the 5th Circuit Court of Appeals.

在第五巡迴上訴法院做出衝突判決後，美國最高法院目前正在評估透過遠端醫療分發 mifepristone 的合法性。

The current legal dispute originates from a challenge by the State of Louisiana against the Food and Drug Administration (FDA). Historically, the FDA mandated in-person clinical visits for the procurement of mifepristone upon its 2000 approval; however, this requirement was relaxed during the COVID-19 pandemic and formalized in 2023 to permit pharmacy dispensing and postal delivery. This policy shift coincided with the Dobbs decision, which eliminated the constitutional right to abortion. Consequently, telemedicine now facilitates approximately 25% of abortions nationwide, contributing to an estimated 1.1 million procedures in 2025, according to Guttmacher Institute data.

目前的法律爭議源於路易斯安那州對美國食品藥物管理局 (FDA) 的挑戰。從歷史來看，FDA 在 2000 年批准 mifepristone 時，要求必須親自前往診所就醫方可獲藥；然而，這項要求在 COVID-19 疫情期間放寬，並於 2023 年正式化，允許藥局分發與郵寄。此次政策轉向與廢除憲法墮胎權的 Dobbs 裁決同時發生。因此，根據 Guttmacher 研究所的數據，遠端醫療目前協助了全國約 25% 的墮胎手術，預計 2025 年將達到 110 萬宗。

Stakeholder positioning reveals a stark divergence in legal and ethical interpretations. The 5th Circuit Court of Appeals, in an opinion authored by Judge Stuart Kyle Duncan, determined that the absence of in-person requirements causes irreparable harm to Louisiana by undermining state prohibitions on abortion and increasing Medicaid expenditures for emergency care. This position is supported by an amicus brief from over 100 Republican lawmakers, who contend that the current regulatory framework facilitates coercion and violates the Comstock Act. Conversely, drug manufacturers Danco Laboratories and GenBioPro, supported by several Democratic-led states and former FDA officials, argue that the medication is safe and that the appeals court's intervention disrupts a science-based regulatory system and restricts access for marginalized or rural populations.

利益相關者的定位顯示，在法律與倫理解釋上存在顯著分歧。第五巡迴上訴法院在由法官 Stuart Kyle Duncan 撰寫的意見書中認定，缺乏親自就醫要求會對路易斯安那州造成不可挽回的損害，因為這削弱了州政府對墮胎的禁令，並增加了 Medicaid 在緊急醫療上的支出。這一立場得到了 100 多名共和黨立法者提交的法庭之友陳述書支持，他們主張目前的監管框架助長了脅迫行為且違反了《康斯托克法案》。相反地，藥廠 Danco Laboratories 和 GenBioPro，在數個民主黨領導的州以及前 FDA 官員的支持下，主張該藥物是安全的，且上訴法院的干預破壞了基於科學的監管體系，並限制了弱勢或鄉村人口的獲取管道。

Administrative and political complexities further complicate the matter. While the Trump administration's Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has initiated a safety review of the drug, the FDA has stated this process remains incomplete. The Department of Justice previously advocated for a deferment of the proceedings. The current legal trajectory is marked by a temporary administrative stay issued by Justice Samuel Alito, which maintains the status quo of telemedicine access until May 11, after which the Court must determine if the in-person requirement will be reinstated nationwide.

行政與政治的複雜性使問題更加複雜。儘管川普政府的衛生及公共服務部在部長 Robert F. Kennedy Jr. 的領導下已啟動對該藥的安全審查，但 FDA 表示此過程尚未完成。司法部此前曾建議推遲訴訟程序。目前的法律軌跡是以法官 Samuel Alito 發出的臨時行政暫緩執行令為標誌，在 5 月 11 日之前維持遠端醫療獲取的現狀，之後法院必須決定是否在全國恢復親自就醫要求。

The legal status of mifepristone distribution remains precarious pending a Supreme Court decision on whether to extend the current stay or reinstate the 5th Circuit's in-person mandate.

mifepristone 分發的法律地位目前仍不穩定，有待最高法院決定是否延長目前的暫緩執行令，或恢復第五巡迴法院的親自就醫要求。